{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T18:03:42Z","timestamp":1793642622753,"version":"4.5.1"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2019,5,27]],"date-time":"2019-05-27T00:00:00Z","timestamp":1558915200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,5,27]],"date-time":"2019-05-27T00:00:00Z","timestamp":1558915200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1007\/s40618-019-01054-1","type":"journal-article","created":{"date-parts":[[2019,5,27]],"date-time":"2019-05-27T02:06:27Z","timestamp":1558922787000},"page":"1273-1283","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":58,"title":["Safety of long-term antithyroid drug treatment? A systematic review"],"prefix":"10.1007","volume":"42","author":[{"given":"F.","family":"Azizi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Malboosbaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,5,27]]},"reference":[{"key":"1054_CR1","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1007\/BF03346433","volume":"31","author":"E Mazza","year":"2008","unstructured":"Mazza E et al (2008) Long-term follow-up of patients with hyperthyroidism due to Graves\u2019 disease treated with methimazole. Comparison of usual treatment schedule with drug discontinuation vs continuous treatment with low methimazole doses: a retrospective study. J Endocrinol Invest 31:866\u2013872","journal-title":"J Endocrinol Invest"},{"key":"1054_CR2","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1007\/s40618-014-0136-z","volume":"37","author":"M Marino","year":"2014","unstructured":"Marino M et al (2014) An update on the medical treatment of Graves\u2019 hyperthyroidism. J Endocrinol Invest 37:1041\u20131048","journal-title":"J Endocrinol Invest"},{"key":"1054_CR3","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1210\/jc.2006-1239","volume":"92","author":"SA Rivkees","year":"2007","unstructured":"Rivkees SA, Dinauer C (2007) An optimal treatment for pediatric Graves\u2019 disease is radioiodine. J Clin Endocrinol Metab 92:797\u2013800","journal-title":"J Clin Endocrinol Metab"},{"key":"1054_CR4","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1210\/jc.2006-1238","volume":"92","author":"JA Lee","year":"2007","unstructured":"Lee JA et al (2007) The optimal treatment for pediatric Graves\u2019 disease is surgery. J Clin Endocrinol Metab 92:801\u2013803","journal-title":"J Clin Endocrinol Metab"},{"key":"1054_CR5","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1210\/jc.2006-2135","volume":"92","author":"H Nakamura","year":"2007","unstructured":"Nakamura H et al (2007) Comparison of methimazole and propylthiouracil in patients with hyperthyroidism caused by Graves\u2019 disease. J Clin Endocrinol Metab 92:2157\u20132162","journal-title":"J Clin Endocrinol Metab"},{"key":"1054_CR6","doi-asserted-by":"crossref","first-page":"3260","DOI":"10.1210\/jc.2009-2546","volume":"95","author":"SA Rivkees","year":"2010","unstructured":"Rivkees SA, Szarfman A (2010) Dissimilar hepatotoxicity profiles of propylthiouracil and methimazole in children. J Clin Endocrinol Metab 95:3260\u20133267","journal-title":"J Clin Endocrinol Metab"},{"key":"1054_CR7","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1089\/thy.2016.0222","volume":"26","author":"JP Brito","year":"2016","unstructured":"Brito JP et al (2016) Antithyroid drugs-the most common treatment for Graves\u2019 disease in the United States: a nationwide population-based study. Thyroid 26:1144\u20131145","journal-title":"Thyroid"},{"key":"1054_CR8","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1089\/thy.2016.0229","volume":"26","author":"DS Ross","year":"2016","unstructured":"Ross DS et al (2016) American thyroid association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid 26:1343\u20131421","journal-title":"Thyroid"},{"key":"1054_CR9","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1089\/thy.1991.1.129","volume":"1","author":"L Wartofsky","year":"1991","unstructured":"Wartofsky L et al (1991) Differences and similarities in the diagnosis and treatment of Graves\u2019 disease in Europe, Japan and the United States. Thyroid 1:129\u2013135","journal-title":"Thyroid"},{"key":"1054_CR10","doi-asserted-by":"crossref","first-page":"4549","DOI":"10.1210\/jc.2012-2802","volume":"97","author":"HB Burch","year":"2012","unstructured":"Burch HB et al (2012) A 2011 survey of clinical practice patterns in the management of Graves\u2019 disease. J Clin Endocrinol Metab 97:4549\u20134558","journal-title":"J Clin Endocrinol Metab"},{"key":"1054_CR11","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1111\/j.1365-2265.2007.03097.x","volume":"68","author":"B Vaidya","year":"2008","unstructured":"Vaidya B et al (2008) Radioiodine treatment for benign thyroid disorders: results of a nationwide survey of UK endocrinologists. Clin Endocrinol (Oxf) 68:814\u2013820","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1054_CR12","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1136\/pmj.76.896.340","volume":"76","author":"F Escobar-Jimenez","year":"2000","unstructured":"Escobar-Jimenez F et al (2000) Trends in diagnostic and therapeutic criteria in Graves\u2019 disease in the last 10 years. Postgrad Med J 76:340\u2013344","journal-title":"Postgrad Med J"},{"key":"1054_CR13","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1089\/thy.2011.2106.ed1","volume":"21","author":"S Yamashita","year":"2011","unstructured":"Yamashita S et al (2011) The American Thyroid Association and American Association of Clinical Endocrinologists hyperthyroidism and other causes of thyrotoxicosis guidelines: viewpoints from Japan and Korea. Thyroid 21:577\u2013580","journal-title":"Thyroid"},{"key":"1054_CR14","doi-asserted-by":"crossref","first-page":"275","DOI":"10.3803\/EnM.2013.28.4.275","volume":"28","author":"JH Moon","year":"2013","unstructured":"Moon JH, Yi KH (2013) The diagnosis and management of hyperthyroidism in Korea: consensus report of the Korean thyroid association. Endocrinol Metab (Seoul) 28:275\u2013279","journal-title":"Endocrinol Metab (Seoul)"},{"key":"1054_CR15","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1007\/s12020-013-9895-0","volume":"44","author":"P Anagnostis","year":"2013","unstructured":"Anagnostis P et al (2013) Predictors of long-term remission in patients with Graves\u2019 disease: a single center experience. Endocrine 44:448\u2013453","journal-title":"Endocrine"},{"key":"1054_CR16","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1089\/ct.2015;27.302-305","volume":"27","author":"J Orgiazzi","year":"2015","unstructured":"Orgiazzi J (2015) Should protracted treatment with antithyroid drug (ATD) be considered as a routine strategy in patients with graves\u2019 disease who had a relapse after a first course of ATD? Clin Thyroidol 27:302\u2013305","journal-title":"Clin Thyroidol"},{"key":"1054_CR17","doi-asserted-by":"crossref","first-page":"R59","DOI":"10.1530\/EJE-16-0938","volume":"177","author":"J L\u00e9ger","year":"2017","unstructured":"L\u00e9ger J, Carel JC (2017) Management of endocrine disease: arguments for the prolonged use of antithyroid drugs in children with Graves\u2019 disease. Eur J Endocrinol 177:R59\u2013R67","journal-title":"Eur J Endocrinol"},{"key":"1054_CR18","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1089\/thy.2016.0652","volume":"27","author":"F Azizi","year":"2017","unstructured":"Azizi F, Malboosbaf R (2017) Long-term antithyroid drug treatment: a systematic review and meta-analysis. Thyroid 27:1223\u20131231","journal-title":"Thyroid"},{"key":"1054_CR19","doi-asserted-by":"publisher","first-page":"339b2700","DOI":"10.1371\/journal.pmed.1000100","volume":"21","author":"A Liberati","year":"2009","unstructured":"Liberati A et al (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 21:339b2700. \n                    https:\/\/doi.org\/10.1371\/journal.pmed.1000100","journal-title":"BMJ"},{"key":"1054_CR20","unstructured":"Wells GA (2001) The Newcastle-Ottawa scale (NOS) for assessing the quality of non randomised studies in meta-analyses. \n                    http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp"},{"key":"1054_CR21","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M et al (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629\u2013634","journal-title":"BMJ"},{"key":"1054_CR22","unstructured":"Centre for Reviews and Dissemination (2009) CRD's guidance for undertaking reviews in healthcare. York Publishing Services. \n                    www.york.ac.uk"},{"key":"1054_CR23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1297\/cpe.26.1","volume":"26","author":"K Yasuda","year":"2017","unstructured":"Yasuda K et al (2017) Relationship between dose of antithyroid drugs and adverse events in pediatric patients with Graves\u2019 disease. Clin Pediatr Endocrinol 26:1\u20137","journal-title":"Clin Pediatr Endocrinol"},{"key":"1054_CR24","first-page":"477","volume":"15","author":"F Azizi","year":"2012","unstructured":"Azizi F et al (2012) Long-term continuous methimazole or radioiodine treatment for hyperthyroidism. Arch Iran Med 15:477\u2013484","journal-title":"Arch Iran Med"},{"key":"1054_CR25","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1210\/jc.2011-1944","volume":"97","author":"J Le\u00b4ger","year":"2012","unstructured":"Le\u00b4ger J et al (2012) Positive impact of long-term antithyroid drug treatment on the outcome of children with Graves\u2019 disease: national long-term cohort study. J Clin Endocrinol Metab 97:110\u2013119","journal-title":"J Clin Endocrinol Metab"},{"key":"1054_CR26","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1089\/thy.2011.0039","volume":"21","author":"P Laurberg","year":"2011","unstructured":"Laurberg P et al (2011) Sustained control of Graves\u2019 hyperthyroidism during long-term low-dose antithyroid drug therapy of patients with severe Graves\u2019 orbitopathy. Thyroid 21:951\u2013956","journal-title":"Thyroid"},{"key":"1054_CR27","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1515\/jpem.2011.194","volume":"24","author":"H Sato","year":"2011","unstructured":"Sato H et al (2011) Comparison of methimazole and propylthiouracil in the management of children and adolescents with Graves\u2019 disease: efficacy and adverse reactions during initial treatment and long-term outcome. J Pediatr Endocrinol Metab 24:257\u2013263","journal-title":"J Pediatr Endocrinol Metab"},{"key":"1054_CR28","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1097\/MNM.0b013e3283134d4d","volume":"30","author":"DY Chen","year":"2009","unstructured":"Chen DY et al (2009) Comparison of the long-term efficacy of low dose 131I versus antithyroid drugs in the treatment of hyperthyroidism. Nucl Med Commun 30:160\u2013168","journal-title":"Nucl Med Commun"},{"key":"1054_CR29","doi-asserted-by":"crossref","first-page":"3817","DOI":"10.1210\/jc.2008-0842","volume":"93","author":"F Kaguelidou","year":"2008","unstructured":"Kaguelidou F, French Childhood Graves\u2019 Disease Study Group et al (2008) Predictors of autoimmune hyperthyroidism relapse in children after discontinuation of antithyroid drug treatment. J Clin Endocrinol Metab 93:3817\u20133826","journal-title":"J Clin Endocrinol Metab"},{"key":"1054_CR30","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1530\/eje.1.01904","volume":"152","author":"F Azizi","year":"2005","unstructured":"Azizi F et al (2005) Effect of long-term continuous methimazole treatment of hyperthyroidism: comparison with radioiodine. Eur J Endocrinol 152:695\u2013701","journal-title":"Eur J Endocrinol"},{"key":"1054_CR31","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1080\/08035250500252872","volume":"94","author":"R Barrio","year":"2005","unstructured":"Barrio R et al (2005) Graves\u2019 disease in children and adolescents: response to long-term treatment. Acta Paediatr 94:1583\u20131589","journal-title":"Acta Paediatr"},{"key":"1054_CR32","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1507\/endocrj.44.553","volume":"44","author":"Y Mashio","year":"1997","unstructured":"Mashio Y et al (1997) Treatment of hyperthyroidism with a small single daily dose of methimazole: a prospective long-term follow-up study. Endocr J 44:553\u2013558","journal-title":"Endocr J"},{"key":"1054_CR33","first-page":"1","volume":"2010","author":"SA Rivkees","year":"2010","unstructured":"Rivkees SA et al (2010) Adverse events associated with methimazole therapy of graves\u2019 disease in children. Int J Pediatr Endocrinol 2010:1\u20134","journal-title":"Int J Pediatr Endocrinol"},{"key":"1054_CR34","doi-asserted-by":"crossref","first-page":"E49","DOI":"10.1210\/jc.2011-2221","volume":"97","author":"N Watanabe","year":"2012","unstructured":"Watanabe N et al (2012) Antithyroid drug-induced hematopoietic damage: a retrospective cohort study of agranulocytosis and pancytopenia involving 50,385 patients with Graves\u2019 disease. J Clin Endocrinol Metab 97:E49\u201353","journal-title":"J Clin Endocrinol Metab"},{"key":"1054_CR35","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1089\/thy.1993.3.335","volume":"3","author":"L Wartofsky","year":"1993","unstructured":"Wartofsky L (1993) Has the use of antithyroid drugs for Graves\u2019 disease become obsolete? Thyroid 3:335\u2013344","journal-title":"Thyroid"},{"key":"1054_CR36","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1365-2265.1991.tb01738.x","volume":"34","author":"JA Franklyn","year":"1991","unstructured":"Franklyn JA et al (1991) Long-term follow up of treatment of hyperthyroidism by three different methods. Clin Endocrinol 34:71\u201376","journal-title":"Clin Endocrinol"},{"key":"1054_CR37","first-page":"85","volume-title":"Hyperthyroidism","author":"EB Astwood","year":"1967","unstructured":"Astwood EB (1967) Use of antithyroid drugs. In: Irvine WJ (ed) Hyperthyroidism. Williams & Wilkins, Baltimore, pp 85\u201398"},{"key":"1054_CR38","first-page":"CD003420","volume":"20","author":"P Abraham","year":"2010","unstructured":"Abraham P et al (2010) Antithyroid drug regimen for treating Graves\u2019 hyperthyroidism. Cochrane Database Syst Rev 20:CD003420","journal-title":"Cochrane Database Syst Rev"},{"key":"1054_CR39","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1007\/s40618-018-0918-9","volume":"41","author":"E Masiello","year":"2018","unstructured":"Masiello E et al (2018) Antithyroid drug treatment for Graves\u2019 disease: baseline predictive models of relapse after treatment for a patient-tailored management. J Endocrinol Invest 41:1425\u20131432","journal-title":"J Endocrinol Invest"},{"key":"1054_CR40","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1530\/eje.1.02295","volume":"155","author":"P Laurberg","year":"2006","unstructured":"Laurberg P (2006) Remission of Graves\u2019 disease during anti-thyroid drug therapy. Time to reconsider the mechanism? Eur J Endocrinol 155:783\u2013786","journal-title":"Eur J Endocrinol"},{"key":"1054_CR41","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1210\/endo.139.1.5658","volume":"139","author":"V Montani","year":"1998","unstructured":"Montani V et al (1998) Regulation of major histocompatibility class II gene expression in FRTL-5 thyrocytes: opposite effects of interferon and methimazole. Endocrinology 139:290\u2013302","journal-title":"Endocrinology"},{"key":"1054_CR42","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1023\/A:1023242732212","volume":"18","author":"E Mozes","year":"1998","unstructured":"Mozes E et al (1998) Spontaneous autoimmune disease in (NZB x NZW) F1 mice is ameliorated by treatment with methimazole. J Clin Immunol 18:106\u2013113","journal-title":"J Clin Immunol"},{"key":"1054_CR43","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1089\/thy.1994.4.217","volume":"4","author":"R Volpe","year":"1994","unstructured":"Volpe R (1994) Evidence that the immunosuppressive effects of antithyroid drugs are mediated through actions on the thyroid cell, modulating thyrocyte-immunocyte signaling: a review. Thyroid 4:217\u2013223","journal-title":"Thyroid"},{"key":"1054_CR44","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1159\/000381768","volume":"2","author":"J Calissendorff","year":"2015","unstructured":"Calissendorff J et al (2015) A prospective investigation of graves\u2019 disease and selenium: thyroid hormones, auto-antibodies and self-rated symptoms. Eur Thyroid J 2:93\u201398","journal-title":"Eur Thyroid J"},{"key":"1054_CR45","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s40618-016-0559-9","volume":"40","author":"M Leo","year":"2017","unstructured":"Leo M et al (2017) Effects of selenium on short-term control of hyperthyroidism due to Graves\u2019 disease treated with methimazole: results of a randomized clinical trial. J Endocrinol Invest 40:281\u2013287","journal-title":"J Endocrinol Invest"},{"key":"1054_CR46","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1159\/000456660","volume":"2","author":"M Marin\u00f2","year":"2017","unstructured":"Marin\u00f2 M et al (2017) Selenium in the treatment of thyroid diseases. Eur Thyroid J 2:113\u2013114","journal-title":"Eur Thyroid J"},{"key":"1054_CR47","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1016\/S0140-6736(11)61452-9","volume":"379","author":"MP Rayman","year":"2012","unstructured":"Rayman MP (2012) Selenium and human health. Lancet 379:1256\u20131268","journal-title":"Lancet"},{"key":"1054_CR48","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1210\/er.2006-0044","volume":"28","author":"M Rotondi","year":"2007","unstructured":"Rotondi M et al (2007) Role of chemokines in endocrine autoimmune diseases. Endocr Rev 28:492\u2013520","journal-title":"Endocr Rev"},{"key":"1054_CR49","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1001\/jama.1979.03300220020015","volume":"242","author":"DW Slingerland","year":"1979","unstructured":"Slingerland DW, Burrows BA (1979) Long-term antithyroid treatment in hyperthyroidism. JAMA 242:2408\u20132410","journal-title":"JAMA"},{"key":"1054_CR50","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1210\/jcem-64-6-1241","volume":"64","author":"BM Lippe","year":"1987","unstructured":"Lippe BM et al (1987) Hyperthyroidism in children treated with Long term medical therapy: twenty-five percent remission every two years. J Clin Endocrinol Metab 64:1241\u20131245","journal-title":"J Clin Endocrinol Metab"},{"key":"1054_CR51","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1089\/thy.2010.0181","volume":"21","author":"L Elbers","year":"2011","unstructured":"Elbers L et al (2011) Outcome of very long-term treatment with antithyroid drugs in Graves\u2019 hyperthyroidism associated with Graves\u2019 orbitopathy. Thyroid 21:279\u2013383","journal-title":"Thyroid"},{"key":"1054_CR52","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1089\/thy.2015.0195","volume":"25","author":"D Villagelin","year":"2015","unstructured":"Villagelin D et al (2015) Outcomes in relapsed graves\u2019 disease patients following radioiodine or prolonged low dose of methimazole treatment. Thyroid 25:1282\u20131290","journal-title":"Thyroid"},{"key":"1054_CR53","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1530\/ERC-12-0176","volume":"19","author":"TT Hieu","year":"2012","unstructured":"Hieu TT et al (2012) Cancer risk after medical exposure to radioactive iodine in benign thyroid diseases: a meta-analysis. Endocr Relat Cancer 19:645\u2013655","journal-title":"Endocr Relat Cancer"},{"key":"1054_CR54","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1515\/jpem-2012-0138","volume":"25","author":"H Sato","year":"2012","unstructured":"Sato H et al (2012) Higher dose of methimazole causes frequent adverse effects in the management of Graves\u2019 disease in children and adolescents. J Pediatr Endocrinol Metab 25:863\u2013867","journal-title":"J Pediatr Endocrinol Metab"},{"key":"1054_CR55","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1089\/thy.2014.0084","volume":"25","author":"S Sato","year":"2015","unstructured":"Sato S et al (2015) Comparison of efficacy and adverse effects between methimazole 15\u00a0mg\u2009+\u2009inorganic iodine 38\u00a0mg\/day and methimazole 30\u00a0mg\/day as initial therapy for Graves\u2019 disease patients with moderate to severe hyperthyroidism. Thyroid 25:43\u201350","journal-title":"Thyroid"},{"key":"1054_CR56","first-page":"1516","volume":"76","author":"D Reinwein","year":"1993","unstructured":"Reinwein D et al (1993) A prospective randomized trial of antithyroid drug dose in Graves\u2019 disease therapy. European Multicenter Study Group on Antithyroid Drug Treatment. J Clin Endocrinol Metab 76:1516\u20131521","journal-title":"J Clin Endocrinol Metab"},{"key":"1054_CR57","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1089\/thy.2008.0364","volume":"19","author":"K Takata","year":"2009","unstructured":"Takata K et al (2009) Methimazole-induced agranulocytosis in patients with Graves\u2019 disease is more frequent with an initial dose of 30\u00a0mg daily than with 15\u00a0mg daily. Thyroid 19:559\u2013563","journal-title":"Thyroid"},{"key":"1054_CR58","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1210\/jcem-57-3-563","volume":"57","author":"JH Romaldim","year":"1983","unstructured":"Romaldim JH et al (1983) Comparison of effects of high and low dosage regimens of antithyroid drugs in the management of Graves\u2019 hyperthyroidism. J Clin Endocrinol Metab 57:563\u2013570","journal-title":"J Clin Endocrinol Metab"},{"key":"1054_CR59","doi-asserted-by":"crossref","first-page":"414","DOI":"10.7326\/0003-4819-77-3-414","volume":"77","author":"JJ Wilberg","year":"1972","unstructured":"Wilberg JJ, Nuttall FQ (1972) Methimazole toxicity from high doses. Ann Intern Med 77:414\u2013416","journal-title":"Ann Intern Med"},{"key":"1054_CR60","doi-asserted-by":"crossref","first-page":"4776","DOI":"10.1210\/jc.2013-2569","volume":"98","author":"H Nakamura","year":"2013","unstructured":"Nakamura H et al (2013) Analysis of 754 cases of antithyroid drug-induced agranulocytosis over 30\u00a0years in Japan. J Clin Endocrinol Metab 98:4776\u20134783","journal-title":"J Clin Endocrinol Metab"},{"key":"1054_CR61","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/bcp.12336","volume":"78","author":"MT Wang","year":"2014","unstructured":"Wang MT et al (2014) Antithyroid drug-related hepatotoxicity in hyperthyroidism patients: a population-based cohort study. Br J Clin Pharmacol 78:619\u2013629","journal-title":"Br J Clin Pharmacol"},{"key":"1054_CR62","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1089\/thy.2014.0350","volume":"25","author":"J Yang","year":"2015","unstructured":"Yang J et al (2015) Analysis of 90 cases of antithyroid drug-induced severe hepatotoxicity over 13\u00a0years in China. Thyroid 25:278\u2013283","journal-title":"Thyroid"},{"key":"1054_CR63","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1089\/thy.2012.0612","volume":"24","author":"H Ohye","year":"2014","unstructured":"Ohye H et al (2014) Antithyroid drug treatment for Graves \u2018disease in children: a long-term retrospective study at a single institution. Thyroid 24:200\u2013207","journal-title":"Thyroid"},{"key":"1054_CR64","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1297\/cpe.20.39","volume":"20","author":"K Minamitani","year":"2011","unstructured":"Minamitani K et al (2011) A report of three girls with antithyroid drug-induced agranulocytosis; retrospective analysis of 18 cases aged 15 years or younger reported between 1995 and 2009. Clin Pediatr Endocrinol 20:39\u201346","journal-title":"Clin Pediatr Endocrinol"},{"key":"1054_CR65","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1111\/j.1365-2265.1989.tb01424.x","volume":"30","author":"H Tamai","year":"1989","unstructured":"Tamai H et al (1989) Methimazole-induced agranulocytosis in Japanese patients with Graves\u2019 disease. Clin Endocrinol 30:525\u2013530","journal-title":"Clin Endocrinol"},{"key":"1054_CR66","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s40618-017-0626-x","volume":"40","author":"Y He","year":"2017","unstructured":"He Y et al (2017) Emphasis on the early diagnosis of antithyroid drug-induced agranulocytosis: retrospective analysis over 16\u00a0years at one Chinese center. J Endocrinol Invest 40:733\u2013740","journal-title":"J Endocrinol Invest"},{"key":"1054_CR67","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1089\/thy.2014.0603","volume":"25","author":"AS Balavoine","year":"2015","unstructured":"Balavoine AS et al (2015) Antineutrophil cytoplasmic antibody-positive small-vessel vasculitis associated with antithyroid drug therapy: how significant is the clinical problem? Thyroid 25:1273\u20131281","journal-title":"Thyroid"},{"key":"1054_CR68","doi-asserted-by":"crossref","first-page":"41","DOI":"10.4038\/sjdem.v3i1.5503","volume":"3","author":"S Abhayaratna","year":"2013","unstructured":"Abhayaratna S, Somasundaram N (2013) The role of long term use of antithyroid drugs in Graves\u2019 disease. Sri Lanka J Diabetes Endocrinol Metabol 3:41\u201344","journal-title":"Sri Lanka J Diabetes Endocrinol Metabol"},{"key":"1054_CR69","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1001\/jama.1967.03130210080013","volume":"202","author":"JE Howard","year":"1967","unstructured":"Howard JE (1967) Treatment of thyrotoxicosis. JAMA 202:706\u2013709","journal-title":"JAMA"},{"key":"1054_CR70","unstructured":"Sattler H (1952) Basedow\u2019s disease. In: Marchand GW, Marchland JF (trans-ed). Grune & Stratton Inc, New York, pp 367\u2013403"},{"key":"1054_CR71","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1136\/bmj.2.5862.332","volume":"2","author":"DG McLarty","year":"1973","unstructured":"McLarty DG et al (1973) Remission of thyrotoxicosis during treatment with propranolol. Br Med J 2:332\u2013334","journal-title":"Br Med J"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-019-01054-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40618-019-01054-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-019-01054-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,25]],"date-time":"2020-05-25T19:32:47Z","timestamp":1590435167000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40618-019-01054-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,27]]},"references-count":71,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["1054"],"URL":"https:\/\/doi.org\/10.1007\/s40618-019-01054-1","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,27]]},"assertion":[{"value":"30 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical statement"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article is a systematic review, so does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants and\/or animals"}},{"value":"For this type of study, formal consent is not required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}